
Modern Methods in Drug Discovery

Aims of this course:


- comprehensive knowledge about all processes in the *drug discovery pipeline*
- in particular *in silico* methods of *drug design*
- perfoming substance queries in databases



Picture source:

https://curesearch.org/Impact-Report-Winter-2016/images/researchpipeline.png

Flow of information in a drug discovery pipeline



Drug Discovery Today

Related topics not covered by this lecture

medicinal chemistry organic synthesis biopharmaceutical aspects (tissue models, non-oral administration) immune system and monoclonal antibodies clinical aspects molecular modelling theory homology modelling theory docking basics and applications computational chemistry genome, proteome, metabolome bioethics, legal aspects, regulatory issues, and patent law



Required knowledge

Use of tools for sequence analysis, e.g. BLAST, CLUSTALO Use of visualizing tools, e.g. BALL, Rasmol, Pymol, VMD, SPDBV

recommended prior courses:

Softwarewerkzeuge der Bioinformatik Computational Chemistry Bioinformatics I + II Structural Bioinformatics

Actual applications during the excerices and homework:


multiple sequence alignment, homology in sequences analyzing protein-ligand interactions SMILES and SMARTS notation of chemical structures using SMARTS with Open Babel Database queries (PubChem, ChEMBL, DrugBank,

ZBI


ZINC, UniProt,...)

What is drug discovery ?

rational and targeted search for new drugs




Typical targets (I)



contribution to the human genome and marketed drugs



Typical targets (II)



Fractional content of marketed drugs according to their biochemical targets

data: Hopkins & Groom, Nat. Rev. Drug. Disc. 1 (2002) 727



Modern Methods in Drug Discovery WS22/23

Preliminary schedule (lectures/topics)

- 1. Introduction, overview, recap of chemical structures
- 2. typical diseases
- 3. properties of drugs and their mode of action
- 4. Substance databases and bioisosteric compounds
- 5. QSAR, statistics and descriptors
- 6. More about QSAR and statistics

- 7. ADME models
- 8. metabolism and toxicology
- 9. target identification, animal models
- 10. cytochrome P450, polymorphisms, transporters
- 11. more complex diseases malaria, obesity, current trends



Preliminary schedule (exercises/tutorials)

Biweekly online via MS-Teams meeting

register for this course in the moodle system

https://lms.sulb.uni-saarland.de/moodle/?lang=en

Naturwissenschaftliche Fakultät/Biowissenschaften/ Bioinformatik(Helms)/Modern Methods in Drug Discovery use "Selbsteinschreibung" (self enrolement) I will add you to the corresponding MS-Team

- discussion of the assignments ۲
- chemical structures of drugs: SMILES and SMARTS
- substance databases and SMARTS queries ٠
- enzyme-ligand interactions, analysis of .pdb files
- using PubChem and ChEMBL databases
- ortholog targets in model organisms Modern Methods in Drug Discovery WS22/23

1st Lecture



Requirements to obtain the certificate and the credit points

- 1. Register for this course in the moodle system.
- 2. Passing the two online tests (will be available in the moodle system) covering the topics of the previous assignments.

 \rightarrow You don't have to hand in the assignments!

50% of all accomplishable points from the final exam taking place at the end of the lecture period. If necessary, repeated (written) exam or oral exam (subject to the corresponding study regulation).
Applies only to students enroled in Bioinformatics: Please register for the exams in the LSF timely.




Compound Databases

Size of typical substance libraries (2022)

12,000,000 chemicals ACD World Drug Index 80,000 compounds commercial <10,000 in clinical trials USAN ≈100,000 compounds virtual library company, in house

- PubChem ChEMBL DrugBank ZINC15
- > 112,000,000 compounds NCBI
 - > 2,200,000 compounds EMBL
 - > 500,000 drugs Uni. Alberta
 - >750,000,000 compounds UCSF






Investment per new chemical entity: >800,000 \$ New chemical entities per year: ca. 15 strongly fluctuating Modern Methods in Drug Discovery WS22/23 11


academic

Methods of Combinatorial Synthesis for High Throughput Screening (HTS)




Selection of compounds for High Throughput Screening (HTS)

Project virtual library of 100,000 members




Predictive ADME




From the pipeline until the commerical launch

For each actual marketed drug (*new chemical enitity*, *NCE*) there have been more than 1000 substances that underwent screened *in vitro*. Without the use of available computer-based ADMET filters, this number would be even larger.




Nature Reviews | Drug Discovery

Why is the prediction of ADME parameters that important ?



Reasons that lead to failure or withdrawl of a potential drug by the mid 1990's


Pharmacokinetics and Bioavailability




(Some) descriptors based on molecular properties used to predict ADME properties


logP water/octanol partitioning coefficient

topological indices count of hydrogen-bonds polar surface area





Multiple linear regression analysis QSAR quantitative structure activity relationship QSPR quantitative structure property rel.



Metabolism

(bio-)chemical reactions of xenobiotics in the body

First pass effect:

Extensive metabolization of mainly lipophilic molecules, such with MW>500, or those that have a specific affinity to certain transporters, during the first passage through the liver

Phase I:

Oxidation, reduction and hydrolysis \rightarrow esp. cytochrome P450 enzymes

Phase II:

Conjugation with small molecules (e.g. glutamine)


mediated by transferases


Phase III:

elimination by transporters



Cytochrome P450 Enzymes (I)






flavin monooxygenase isoenzyme (FMO) monoamine dehydrogenase (MAO) aldo-keto reductase (AKR) alcohol dehydrogenase aldehyde oxidase

Further phase I enzymes

1st Lecture



Modern Methods in Drug Discovery WS22/23

Cytochrome P450 polymorphism

"Every human is (more or less) different"

Determination of the phenotype by the actual activity or the amount of the expressed enzyme.

In contrast, the genotype is determined by the individual DNA sequence.


Thus, the same genotype enables several different phenotypes

According to their metabolic activity of CYP there is a classification into normal (*extensive metabolizer*), weak (*poor metabolizer*), und accelerated (*ultra-rapid metabolizer*) metabolism.

Lit: K. Nagata et al. Drug Metabol. Pharmacokin 3 (2002) 167

Genotyping of CYP P450 alleles

By using immobilized, synthetic copies of P450 nucleotides, the Affymetrix company (USA) has developped mircoarrays (gene chips) that allow the identification of all clinically relevant alleles.



Prediction of molecular properties (I)

The keynote of rational drug design

The general question is:

What is the connection between the biological space (activity) and the chemical space (structure)?

How are we able to make structure-based prediction ?

- \rightarrow QSAR and QSRP, regression analysis
- \rightarrow decision trees, machine learning algorithms
- \rightarrow other statistical methods



Prediction of molecular properties (II)

What are (physial) molecular properties?

molecular weight MW (from the sum formula $C_{12}H_{11}N_3O_2$) melting point boiling point vapour pressure solubility (in water) charge **Directly computable** dipole moment from the electronic polarizability wave function of a ionization potential molecule electrostatic potential





1st Lecture

observables

BBB-model with 12 descriptors


Descriptors mainly from QM calculations: electrostatic surface, principal components of molecular geometry, H-bond properties





Lit: M. Hutter *J.Comput.-Aided.Mol.Des.* **17** (2003) 415. 1st Lecture Modern Methods in Drug Discovery WS22/23

Cycle of optimization in the drug discovery pipeline



Source: D.K. Agrafiotis et al. Nature. Rev. Drug. Discov. 1 (2002) 337.

Modern Methods in Drug Discovery WS22/23

Accompanying books and further reading (I)

Molekulare Genetik


Andrew R. Leach* Molecular Modelling. Principles and Applications 2nd edition, Prentice Hall, 2001

Rolf Knippers* Molekulare Genetik 8. Auflage, Thieme, 2001


The Merck Index* 13th edition, Merck & CO., Inc., 2001

J.M. Berg, L. Stryer* Biochemie, Spektrum Verlag Biochemistry, W.H. Freeman & Co Ltd.

*Available in the "Semesterapparat"



17 Thierry







Accompanying books and further reading (II)


Gerhard Klebe* Wirkstoffdesign 2. Auflage, Spektrum Akad. Verlag, 2009

C.A. Orengo, D.T. Jones, J.M. Thornton* Bioinformatics Genes, Proteins & Computers 1st ed., Bios Scientific Publishers, 2003


A.R. Leach, V. Gillet* An Introduction to Chemoinformatics revised ed., Springer, 2007

*Available in the "Semesterapparat" located at the library in E2.3






Wirkstoffdesign Entwurf und Wirkung





Further hands-on tools

Molecular model sets / Molekülbaukasten



Commerically available at various price ranges




Other useful software to make nice pictures

Chemical structures and other objects: C-Design 3.0f Windows-Platform

Protein structures: PyMOL www.pymol.org Linux, Mac OS X, Windows





1st assignment (I)

Refer to a prescription medicine of your own choice


Write down the active ingridient

Try to find out its molecular structure:

https://pubchem.ncbi.nlm.nih.gov/

NIH U.S. National Library of Medicine National Center for Biotechnology Information	
Public About Blog Submit Contact PubChem presents at the American Chemical Society National Meeting in San Diego (August 25-29, 2019) Read More >	
Explore Chemistry Quickly find chemical information from authoritative sources	
capoten Q	
Try aspirin EGFR C9H8O4 57-27-2 C1=CC=C(C=C1)C=O InChI=1S/C3H6O/c1-3(2)4/h1-2H3	
1st 😪 🚊 🗄 🛄	\rangle

1st assignment (II)



COMPOUND BEST MATCH

	Captopril; 62571-86-2; L-Captopril; Capoten; Lopirin; Captopryl; Cesplon; Tensoprel;
	Compound CID: 44093
1	MF: C ₉ H ₁₅ NO ₃ S MW: 217.29g/mol
	InChIKey: FAKRSMQSSFJEIM-RQJHMYQMSA-N
	IUPAC Name: (2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid
	Create Date: 2005-06-24
Summary	Similar Structures Search Related Records PubMed (MeSH Keyword)

Compounds	Substances	Literature
(2)	(19)	(80)

Searching chemical names and synonyms including IUPAC names and InChIKeys accross the compound collection. Note that annotations text from compound summary pages is not searched. Read More...

1st assignment (III)

PubChem Captopril (Compound)

7 Drug and Medication Information	? Z
7.1 Drug Indication	? Z

For the treatment of essential or renovascular hypertension (usually administered with other drugs, particularly thiazide diuretics). May be used to treat congestive heart failure in combination with other drugs (e.g. cardiac glycosides, diuretics, β-adrenergic blockers). May improve survival in patients with left ventricular dysfunction following myocardial infarction. May be used to treat nephropathy, including diabetic nephropathy.

from DrugBank

Treatment of heart failure

from European Medicines Agency (EMA)

7.2 LiverTox Summary

Captopril is an angiotensin-converting enzyme (ACE) inhibitor used in the therapy of hypertension and heart failure. Captopril is associated with a low rate of transient serum aminotransferase elevations and has been linked to rare instances of acute liver injury.

from LiverTox



Angiotensin-Converting Enzyme Inhibitors

5 Related Records • 6 Chemical Vendors • 7 Drug and Medication Information • 8 Pharmacology and Biochemistry • 9 Use and Manufacturing • 10 Identification • 11 Safety and Hazards • 12 Toxicity •	F Share 🎔 Tweet 🎴	Ema
5 Related Records • 6 Chemical Vendors • 7 Drug and Medication Information • 8 Pharmacology and Biochemistry • 9 Use and Manufacturing • 10 Identification • 11 Safety and Hazards • 12 Toxicity • 13 Literature • 15 Biomolecular Interactions and Pathways • 16 Biological Test Results •	💔 Cite 👤 Dow	nload
5 Related Records 6 Chemical Vendors 7 Drug and Medication Information 8 Pharmacology and Biochemistry 9 Use and Manufacturing 10 Identification 11 Safety and Hazards 12 Toxicity 13 Literature 15 Biomolecular Interactions and Pathways 16 Biological Test Results	CONTENTS	Ŷ
6 Chemical Vendors 7 Drug and Medication Information 8 Pharmacology and Biochemistry 9 Use and Manufacturing 10 Identification 11 Safety and Hazards 12 Toxicity 13 Literature 14 Patents 15 Biomolecular Interactions and Pathways 16 Biological Test Results *		~
Information 8 Pharmacology and Biochemistry * 9 Use and Manufacturing * 10 Identification * 11 Safety and Hazards * 12 Toxicity * 13 Literature * 15 Biomolecular Interactions and Pathways * 16 Biological Test Results *		
Biochemistry * 9 Use and Manufacturing * 10 Identification * 11 Safety and Hazards * 12 Toxicity * 13 Literature * 14 Patents * 15 Biomolecular Interactions and Pathways * 16 Biological Test Results *		~
10 Identification ~ 11 Safety and Hazards ~ 12 Toxicity ~ 13 Literature ~ 14 Patents ~ 15 Biomolecular Interactions and Pathways ~ 16 Biological Test Results ~		Ň
11 Safety and Hazards ~ 12 Toxicity ~ 13 Literature ~ 14 Patents ~ 15 Biomolecular Interactions and Pathways ~ 16 Biological Test Results ~	9 Use and Manufacturing	~
12 Toxicity • 13 Literature • 14 Patents • 15 Biomolecular Interactions and Pathways • 16 Biological Test Results •	10 Identification	~
13 Literature • 14 Patents • 15 Biomolecular Interactions and Pathways • 16 Biological Test Results •	11 Safety and Hazards	~
14 Patents ~ 15 Biomolecular ~ Interactions and Pathways ~ 16 Biological Test Results ~	12 Toxicity	~
15 Biomolecular Interactions and Pathways 16 Biological Test Results ~	13 Literature	~
Interactions and Pathways 16 Biological Test Results ~	14 Patents	~
-	Interactions and	~
17 Classification ~	16 Biological Test Results	~
	17 Classification	~

Explain why the medicine has a completely different name compared to the actual substance.

 $\bigcirc \square$

 $\bigcirc \ \square$


Try to find out some information about its actual *molecular target* (here: Angiotensin-Coverting Enzyme) e.g. using Wikipedia

1st Lecture

Modern Methods in Drug Discovery WS22/23


Recapitulation: The Chemical Bond

Entirely covalent, ionic, or metallic bonds between atoms are the extrem cases. More often the actual kind of bonding is somewhere in between and is subject to the difference in electronegativity of the atoms/elements involved.



Representation of chemical structures (I)

The valence electrons of the atoms are pairwise grouped together




Such Lewis structures reflect covalent bonds between atoms in a molecule.

Therefore any molecule can be regarded as graph with the atoms being the nodes and the bonds as vertices.




Representation of chemical structures (II)

(electron) lone pairs are often not shown for visual clarity




octet rule and hypervalent atoms

Equal bond lengths!




 $O^{-}_{-} = O^{-}_{-} O^$





Representation of chemical structures (III)




Corners and end of lines denote carbon atoms saturated with the appropriate number of hydrogen atoms




Representation of chemical structures (IV)

Stereochemistry



Solid wedges denote atoms in front of the plane,dashed wedges denote atoms behind

Four different substituents at a carbon atom cause chirality. Similar: silicon, sulfur, phosphorus,...






Examples: Most amino acids, sugars, many natural compounds,...

Representation of chemical structures (V)

Particular for more complex molecules, these 2D structural drawings provide more clarity than a picture of an actual 3D representation does.



Exercise: Construct this molecule using a molecular model set. Specify the chiral carbon atoms.



Bond distances and bond dissociation energies (I)


bond	distance [Å]	D _o [kJ/mol] (h	nomolytic cleavage)
H–H	0.742	432	e.g. H• •H
C–H	1.09 ± 0.01	411 ± 7	
C–C	1.54	345	
C=C	1.34 - 1.40*	602 ± 21	*aromatic bond
C≡C	1.20	835	
C–N	1.47	305	longor
C=N	1.35	615	longer
C≡N	1.16	887	H He
C–O	1.43	358	Li Be B C N O F Ne Na Mg AI Si P S CI Ar
C=O	1.20	526	Na Mg Al Si P S Cl Ar K Ca Ga Ge As Se Br Kr Rb Sr In Sn Sb Te I Xn
C–Si	1.85	318	RbSrInSnSbTeIXnCsBaTIPbBiPoAtRn
C–P	1.84	264	
C–S	1.82	272	Adapted from: J.E.Huheey
C=S	1.60	577 ± 21	Inorganic Chemistry, Wiley.

Bond distances and bond dissociation energies (II)

bond	distance [Å]	D _o [kJ/mol]	
C–F	1.35	485	
C–Cl	1.77	327	
C–Br	1.94	285	
C–I	2.14	213	
C–H	1.09	411 non-po	olar hydrogen
O–H	0.96	459 J	polar hydrogens,
N–H	1.01	386 ± 8	exchangable in polar
S–H	1.34	363 ± 5	solvents, e.g. water
N–N	1.45	247 ± 13	reason:
N=N	1.25	418	N, O, and S are more
N–O	1.40	201	electronegative than C;
N=O	1.21	607	heterolytic cleavage
P–O	1.63	≈335	that leads to ions
P=0	≈1.50	≈544	e.g. O⁻ H⁺

Bond angles (I)

Strongly dependend on the hybridization




The C–C σ -bond is formed by overlap of the 1s orbitals

These are hybrizided atomic orbitals. Do not confuse with molecular orbitals (=linear combination of atomic orbitals)

Molecular Orbitals

MO = linear combination of atomic orbitals (LCAO)


 π -bond of ethylene H₂C=CH₂



The two combinations usually result in one bonding and one anti-bonding MO

Bond angles (II)

Extreme deviations from ideal bond angles




gives rise to strain energy in small rings

 \rightarrow problems in force fields. More than one atom type for each hybridization state (e.g. Csp^3) neccessary.


Chiral atoms

Further elements showing chirality/stereochemistry (the lone electron pair behaves like a substituent)



Furthermore: As, Si, ..., compounds with transition elements, esp. octahedral and square planar metal complexes e.g. Pt


Isomers



Source: enhanced from wikipedia

Question: Which kind of computational method(s) allow(s) to calculate differences in energy between the respective isomers ?

Is stereochemistry important ?



Data from 1982: Böhm, Klebe & Kubinyi, Wirkstoffdesign